Cardiotoxicity Clinical Trial
Official title:
Official Title: Remote 1-minute Single-lead Electrocardiogram (ECG) Monitoring for Cardiotoxicity Detection in Patients With the First Diagnosed Cancer After the First Cycle of Polychemotherapy
This research is a multi-center prospective cohort interventional study aimed to determinate the capabilities of remote 1-minute single-lead electrocardiogram monitoring for cardiotoxicity detection, during two- three weeks (depending on the scheme of polychemotherapy) after the first cycle of polychemotherapy in patients with the first diagnosed cancer.
The study planned to include 130 patients and will be conducted in three stages: Stage one - screening (the day before chemotherapy treatment): 1. Signing a voluntary informed consent to participate in the study; 2. Clinical examination; Questioning: finding out the complaints. Anamnesis morbid: investigation of the history of cardiovascular diseases (the presence of hypertension, ischemic heart disease, diabetes mellitus, congenital heart disease, heart surgery in the past). Anamnesis vitae: investigation of the history of patient's life (place of birth, development in childhood and adolescence, tobacco smoking, consumption of alcohol beverage, narcotic drugs, sleeping pills and sedatives, strong tea and coffee). 3. Assessment patient's risk profile according to the cardiotoxicity risk assessment scale for treatment of tumors (C.M. Larsen assessment scale 2014). Risk level-the sum of points of all risks ((1) the risk associated with the specific chemotherapy that will be received and (2) the risk related to co-existing cardiac risk factors, age and sex of patients), these factors can be used to generate a risk score: >6 points-very high risk, 5-6 points - high risk; 3-4 points- intermediate risk; 1-2 points-rare risk; 4. All patients included in the study will be registered in single-lead ECG server base and will be trained to use single-lead electrocardiograph themselves. Before starting chemotherapy, each patient will record an 1-minute single-lead ECG. 5. Instrumental examination: transthoracic echocardiography with assessment of left ventricular ejection fraction (LVEF) and speckle-tracking global longitudinal strain (GLS), standard 12-lead electrocardiography; 6. Laboratory testing: cardiac serum biomarkers-n-terminal pro b-type natriuretic peptide(NT-proBNP), highly sensitive troponin I. Stage two - interim home control (during 2-3 weeks after first cycle of the chemotherapy): During this period, patients will registrate a single-lead electrocardiogram by themselves using single-lead ECG device, every day the patient should do at least 5 ECG records. The data will be sent to the server database, where cardiologist will check it for pathology, poor quality and will contact patients, if needed. Stage three - final control (after first course of the chemotherapy): 1. Patients' clinical examination, complaints registration; 2. Instrumental examination: transthoracic echocardiography with assessment of left ventricular ejection fraction (LVEF) and speckle-tracking global longitudinal strain (GLS), standard 12-lead electrocardiography; 3. Laboratory testing:cardiac serum biomarkers -n-terminal pro b-type natriuretic peptide (NT-proBNP), highly sensitive troponin I); 4. Evaluation of outcomes,depending on the patient's complaints, the results of instrumental and biochemical test methods carried out. The patient will be given recommendations necessary for their cardiovascular disorders correction; 5. Database compilation and statistical processing. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05271162 -
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
|
Phase 3 | |
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Recruiting |
NCT04092309 -
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
|
N/A | |
Recruiting |
NCT04790266 -
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
|
||
Enrolling by invitation |
NCT04305613 -
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
|
||
Not yet recruiting |
NCT05040867 -
Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients
|
N/A | |
Recruiting |
NCT05851053 -
Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
|
||
Recruiting |
NCT05992337 -
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
|
||
Enrolling by invitation |
NCT04877899 -
Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
|
||
Recruiting |
NCT05096338 -
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
|
||
Recruiting |
NCT05078190 -
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast Cancer
|
||
Recruiting |
NCT04632407 -
Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study?
|
N/A | |
Completed |
NCT00543062 -
Staccato Prochlorperazine Thorough QT/QTc
|
Phase 1 | |
Recruiting |
NCT05159479 -
Defining Robust Predictors of Chemotherapy Related Cardiotoxicity
|
||
Not yet recruiting |
NCT06005259 -
Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)
|
Phase 4 | |
Recruiting |
NCT05406635 -
Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT04047901 -
Effect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer Treatment
|
N/A | |
Terminated |
NCT03038997 -
Early Detection of Cardiac Toxicity in Childhood Cancer Survivors
|
||
Completed |
NCT01246778 -
Sunitinib and Atrial Trabeculae Contractility
|
N/A |